Tanios Bekaii-Saab, MD, is the section chief for the gastrointestinal oncology program and the chair for the Gastrointestinal Disease-Specific Research Group at the OSUCCC – James. In Ohio State’s College of Medicine, he is a tenured associate professor in the Department of Internal Medicine, Division of Medical Oncology, and in the Department of Pharmacology. Bekaii-Saab’s research focuses on drug development and experimental therapeutics as pertaining to gastrointestinal malignancies. He is the principal investigator on numerous clinical trials, including studies supported by grants from the National Cancer Institute (NCI), the National Comprehensive Cancer Network (NCCN) and various industry partners. He has authored multiple publications in high-impact scientific journals, including Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research amongst others. He has presented his research at multiple national and international forums. He is also on the editorial board for the Journal of the National Comprehensive Cancer Network and has received numerous leadership awards from various organizations such as NCI and ASCO. He is one of the “Best Doctors in America” as well as a “Top Castle Connolly Doctor”. Dr. Bekaii-Saab earned his medical degree at the American University of Beirut in Lebanon, did his residency in internal medicine at the Indiana University Medical Center in Indianapolis, and completed fellowships in hematology/oncology and in clinical pharmacology at Tufts University-New England Medical Center in Boston. He joined Ohio State’s medical faculty in 2002.
Dr. Antonia Sepulveda is Vice-Chair for Translational Research and Director of the Division of Gastrointestinal Pathology in the Department of Pathology & Cell Biology at Columbia University. Dr. Sepulveda is an experienced gastrointestinal and molecular pathologist with expertise combining conventional morphology and novel molecular applications for tissue diagnosis. Her clinical expertise is focused in Gastrointestinal and Pancreaticobiliary Pathology and her Molecular Pathology expertise is centered in solid tumor genomic and epigenetic molecular testing. She has served as the Chair of the Solid Tumor Subdivision of the Association for Molecular Pathology. Dr. Sepulveda’s research laboratory and the pathology translational research program at Columbia University are integrating conventional diagnostics with novel molecular testing applications of molecular biomarkers, with emphasis in genomic and epigenetic approaches for evaluation of cancer risk, diagnosis, prognosis and targeted therapies in digestive organ cancers and precursor lesions, including gastric, esophageal, colorectal and pancreaticobiliary tumors. Dr. Sepulveda has contributed numerous original research publications, reviews and chapters and is the Editor of a recently released book titled "Molecular Pathology of Neoplastic Gastrointestinal Diseases".
Bassel F. El-Rayes, M.D. is the Director of the GI Oncology Clinical and Translational Research Program, Associate Cancer Research Director for Clinical Research at Winship Cancer Institute of Emory University and Associate Professor of Hematology and Oncology at Emory University School of Medicine. Dr. El-Rayes earned his bachelor’s degree in biology and doctoral degree from the American University of Beirut. He then completed his residency in internal medicine and fellowship in hematology and medical oncology at Wayne State University, Detroit. He is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology and is an active member of the American Society of Clinical Oncology. He was on faculty at Wayne State University Karmanos Cancer Institute from 2003-2009. Dr El-Rayes clinical interests include gastrointestinal malignancies. Dr El-Rayes is a Georgia Cancer Coalition Distinguished Clinical Scholar. He has published over 75 peer reviewed articles in elite journals including Journal of Clinical Oncology and Cancer Research.
Christina S. Wu, M.D., is an Assistant Professor of Internal Medicine in the Division of Medical Oncology at The Ohio State University-James Cancer Hospital and Solove Research Institute, Columbus, Ohio. Dr. Wu’s clinical interests include gastrointestinal malignancies and her research is focused on colorectal cancer and high risk colon cancer. She completed her medical school at the University of Dublin, Trinity College, Ireland and a post-doctoral research fellowship at Boston University School of Medicine in Boston, Massachusetts followed by her Internal Medicine Residency at the University of Massachusetts in Worcester, Massachusetts. Dr. Wu completed her training with a Hematology/Oncology Fellowship at Lombardi Comprehensive Cancer Center at Georgetown University Hospital in Washington D.C.
Dear Therapy Finder® User:
During the past two years we have witnessed an unprecedented upswing in research activity leading to the identification of increasing numbers of actionable biomarkers and several effective targeted treatments. To accommodate this dramatic increase in the number of relevant biomarkers, their interactions, and other patient attributes, we are developing a new application design, one that will be both easier to use and more relevant to practicing physicians and patients. This new system will unify many of the best features and key learnings from the Therapy Finders with those from our Genomic Variant Annotation™ (GVA) reporting system.
Until we complete the redesign of our Therapy Finders or offer substitute decision-support products, we are suspending the updating of the Therapy Finders appearing on the CollabRx website and other sites.
If you click through and decide to use the Colon Cancer, Lung Cancer, Melanoma or Metastatic Breast Cancer Therapy Finders, please do so with caution, as some of the data have not been updated since October 15, 2014.
July 6, 2015